Ameritas Investment Partners’s Gyre Therapeutics GYRE Stock Holding History

Ameritas Investment Partners’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.76K	Hold	683	–	–	﹤0.01%	2996
2025 Q4	$4.82K	Hold	683	–	–	﹤0.01%	3033
2025 Q3	$5.09K	Hold	683	–	–	﹤0.01%	3058
2025 Q2	$5.02K	Hold	683	–	–	﹤0.01%	3109
2025 Q1	$5.27K	Hold	683	–	–	﹤0.01%	2962
2024 Q4	$8.26K	Hold	683	–	–	﹤0.01%	2949
2024 Q3	$8.56K	Hold	683	–	–	﹤0.01%	2964
2024 Q2	$8.15K	Buy	+683	New	+$9.37K	﹤0.01%	2981
2021 Q2	–	Sell	-205	Closed	-$8K	–	3138
2021 Q1	$8K	Hold	205	–	–	﹤0.01%	2921
2020 Q4	$10K	Hold	205	–	–	﹤0.01%	2782
2020 Q3	$7K	Hold	205	–	–	﹤0.01%	2870
2020 Q2	$9K	Buy	+205	New	+$9.63K	﹤0.01%	2772
2019 Q2	–	Sell	-132	Closed	-$8K	–	3076
2019 Q1	$8K	Hold	132	–	–	﹤0.01%	2760
2018 Q4	$8K	Hold	132	–	–	﹤0.01%	2740
2018 Q3	$11K	Hold	132	–	–	﹤0.01%	2798
2018 Q2	$12K	Buy	+132	New	+$23.2K	﹤0.01%	2779

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ameritas Investment Partners's GYRE Position: Q1 2026 in Review

Ameritas Investment Partners held its Gyre Therapeutics (GYRE) position steady in Q1 2026 at 683 shares worth $4.76K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Ameritas Investment Partners first reported a position in GYRE in Q2 2018 and has held it in 16 quarters since. The position peaked at $12K in Q2 2018. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

Ameritas Investment Partners held 683 shares of Gyre Therapeutics worth $4.76K as of Q1 2026.
Ameritas Investment Partners left its Gyre Therapeutics share count unchanged in Q1 2026.
Gyre Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2996 holding.
Ameritas Investment Partners first reported a position in Gyre Therapeutics in Q2 2018 and has held it in 16 quarters since.
Ameritas Investment Partners's Gyre Therapeutics position peaked at $12K in Q2 2018.
56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.